The results from the FORWARD II trial (NCT02606305) indicated that eighteen women with relapsed FRα‐positive and platinum‐sensitive ovarian cancer were treated with carboplatin in combination with mirvetuximab soravtansine.263. The gene discussed is FOLR1; the disease is ovarian carcinoma.